Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores

Adynxx

Status and phase: Withdrawn; Phase 2

Conditions: Pain, Postoperative

Treatments: Drug: Brivoligide Injection 660 mg/6 mL; Drug: Placebo 6 mL

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT04104919

ADYX-006

1UG3DA048375-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This is a multiple center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection administered intrathecally before surgery in patients with high Pain Catastrophizing Scale (PCS) scores undergoing mastectomy with immediate tissue expander or implant placement.

Full description

Potential subjects will be prescreened for PCS score; pre-qualified patients will be invited to the investigative site for informed consent and full screening within 30 days of randomization. Patients providing informed consent and meeting all study eligibility criteria will be enrolled in the study on the day of surgery (Day 1).

Subjects will receive study drug just prior to anesthesia induction. Study assessments will be entered by subjects in the electronic diary from Day 1 through Day 21. Follow-up visits will occur on Days 7 and 21 (± 2 days).

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Score of 16 or greater on the PCS scale
• Scheduled to undergo unilateral or bilateral mastectomy with immediate tissue expander or implant placement
• American Society of Anesthesiologists Physical Status Classification System ≤ 3
• Medically stable for this surgery with general anesthesia and intrathecal administration of study drug as determined by the Investigator
• Body mass index of 18-45 kg/m2
• Have a stable medical regimen (for prescribed medications) for ≥ 7 days before randomization
• Able to read and understand study instructions in English or Spanish, and willing and able to comply with all study procedures

Exclusion criteria

• Prior breast surgery in the index breast (either breast for bilateral surgery) in the last two years, other than biopsies and small/moderate volume lumpectomies
• Induction chemotherapy or plans for adjunctive chemotherapy or any radiotherapy within 21 days of surgery
• Known spinal deformities or cutaneous infection in the lumbar area that would preclude intrathecal administration of study drug
• Planned use of liposomal formulated or long-acting local anesthetics, extended release opioid formulations (e.g., Oxycontin), long half-life opioids (e.g., methadone), or drugs with potential for adverse cognitive or memory effects (e.g., ketamine, scopolamine, or propranolol) preoperatively and/or at any time through the duration of the study
• Use of more than 40 mg per day (on average) of oral morphine or its equivalent within 1 month prior to randomization
• Current neurologic disorder, which could confound the assessment of pain
• Unstable mental condition which would prevent the patient from understanding the nature and scope of the study and/or evidence of an uncooperative attitude in the opinion of the Investigator
• Women who are pregnant or nursing
• Participation in a clinical trial with the last dose or intervention within 1 month of randomization, or planned treatment in a clinical trial during this study
• Previous participation in any study involving brivoligide injection

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

Brivoligide Injection 660 mg/6 mL

Experimental group

Description:

Subjects randomized to the brivoligide treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.

Treatment:

Drug: Brivoligide Injection 660 mg/6 mL

Placebo 6 mL

Placebo Comparator group

Description:

Subjects randomized to the placebo group will receive a single 6 mL intrathecal administration of placebo while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.

Treatment:

Drug: Placebo 6 mL